BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

790 related articles for article (PubMed ID: 28274850)

  • 1. Direct-Acting Antiviral Therapy Restores Immune Tolerance to Patients With Hepatitis C Virus-Induced Cryoglobulinemia Vasculitis.
    Comarmond C; Garrido M; Pol S; Desbois AC; Costopoulos M; Le Garff-Tavernier M; Si Ahmed SN; Alric L; Fontaine H; Bellier B; Maciejewski A; Rosenzwajg M; Klatzmann D; Musset L; Poynard T; Cacoub P; Saadoun D
    Gastroenterology; 2017 Jun; 152(8):2052-2062.e2. PubMed ID: 28274850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Sofosbuvir Plus Daclatasvir for Treatment of HCV-Associated Cryoglobulinemia Vasculitis.
    Saadoun D; Pol S; Ferfar Y; Alric L; Hezode C; Si Ahmed SN; de Saint Martin L; Comarmond C; Bouyer AS; Musset L; Poynard T; Resche Rigon M; Cacoub P
    Gastroenterology; 2017 Jul; 153(1):49-52.e5. PubMed ID: 28288791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Sofosbuvir and Daclatasvir in Patients With Fibrosing Cholestatic Hepatitis C After Liver Transplantation.
    Leroy V; Dumortier J; Coilly A; Sebagh M; Fougerou-Leurent C; Radenne S; Botta D; Durand F; Silvain C; Lebray P; Houssel-Debry P; Kamar N; D'Alteroche L; Petrov-Sanchez V; Diallo A; Pageaux GP; Duclos-Vallee JC;
    Clin Gastroenterol Hepatol; 2015 Nov; 13(11):1993-2001.e1-2. PubMed ID: 26044317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection.
    Sulkowski MS; Vargas HE; Di Bisceglie AM; Kuo A; Reddy KR; Lim JK; Morelli G; Darling JM; Feld JJ; Brown RS; Frazier LM; Stewart TG; Fried MW; Nelson DR; Jacobson IM;
    Gastroenterology; 2016 Feb; 150(2):419-29. PubMed ID: 26497081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term Efficacy of Interferon-Free Antiviral Treatment Regimens in Patients With Hepatitis C Virus-Associated Cryoglobulinemia Vasculitis.
    Cacoub P; Si Ahmed SN; Ferfar Y; Pol S; Thabut D; Hezode C; Alric L; Comarmond C; Ragab G; Quartuccio L; Hegazy M; Poynard T; Resche Rigon M; Saadoun D
    Clin Gastroenterol Hepatol; 2019 Feb; 17(3):518-526. PubMed ID: 29857143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents.
    Sise ME; Bloom AK; Wisocky J; Lin MV; Gustafson JL; Lundquist AL; Steele D; Thiim M; Williams WW; Hashemi N; Kim AY; Thadhani R; Chung RT
    Hepatology; 2016 Feb; 63(2):408-17. PubMed ID: 26474537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection.
    Fontana RJ; Brown RS; Moreno-Zamora A; Prieto M; Joshi S; Londoño MC; Herzer K; Chacko KR; Stauber RE; Knop V; Jafri SM; Castells L; Ferenci P; Torti C; Durand CM; Loiacono L; Lionetti R; Bahirwani R; Weiland O; Mubarak A; ElSharkawy AM; Stadler B; Montalbano M; Berg C; Pellicelli AM; Stenmark S; Vekeman F; Ionescu-Ittu R; Emond B; Reddy KR
    Liver Transpl; 2016 Apr; 22(4):446-58. PubMed ID: 26890629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Direct Acting Antivirals in Kidney Transplant Recipients with Chronic Hepatitis C Virus Infection.
    Lin MV; Sise ME; Pavlakis M; Amundsen BM; Chute D; Rutherford AE; Chung RT; Curry MP; Hanifi JM; Gabardi S; Chandraker A; Heher EC; Elias N; Riella LV
    PLoS One; 2016; 11(7):e0158431. PubMed ID: 27415632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PEGylated interferon alfa-2b and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis.
    Cacoub P; Saadoun D; Limal N; Sene D; Lidove O; Piette JC
    Arthritis Rheum; 2005 Mar; 52(3):911-5. PubMed ID: 15751068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study.
    Saadoun D; Thibault V; Si Ahmed SN; Alric L; Mallet M; Guillaud C; Izzedine H; Plaisier A; Fontaine H; Costopoulos M; Le Garff-Tavernier M; Hezode C; Pol S; Musset L; Poynard T; Cacoub P
    Ann Rheum Dis; 2016 Oct; 75(10):1777-82. PubMed ID: 26567178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia.
    Gragnani L; Visentini M; Fognani E; Urraro T; De Santis A; Petraccia L; Perez M; Ceccotti G; Colantuono S; Mitrevski M; Stasi C; Del Padre M; Monti M; Gianni E; Pulsoni A; Fiorilli M; Casato M; Zignego AL
    Hepatology; 2016 Nov; 64(5):1473-1482. PubMed ID: 27483451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of simeprevir plus sofosbuvir with or without ribavirin in patients with decompensated genotype 1 hepatitis C cirrhosis.
    Modi AA; Nazario H; Trotter JF; Gautam M; Weinstein J; Mantry P; Barnes M; Habib A; McAfee J; Teachenor O; Tujague L; Gonzalez S
    Liver Transpl; 2016 Mar; 22(3):281-6. PubMed ID: 26335142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recurrent Mixed Cryoglobulinemia Despite Sustained Virologic Response to Treatment: A Case Report.
    Chowdhury R; Tsen A
    Am J Kidney Dis; 2017 Aug; 70(2):301-304. PubMed ID: 28343737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of clinical and virologic responses to antiviral treatment and regulatory T cell evolution in patients with hepatitis C virus-induced mixed cryoglobulinemia vasculitis.
    Landau DA; Rosenzwajg M; Saadoun D; Trébeden-Negre H; Klatzmann D; Cacoub P
    Arthritis Rheum; 2008 Sep; 58(9):2897-907. PubMed ID: 18759287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Restoration of peripheral immune homeostasis after rituximab in mixed cryoglobulinemia vasculitis.
    Saadoun D; Rosenzwajg M; Landau D; Piette JC; Klatzmann D; Cacoub P
    Blood; 2008 Jun; 111(11):5334-41. PubMed ID: 18292291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased peripheral CD4
    Langhans B; Nischalke HD; Krämer B; Hausen A; Dold L; van Heteren P; Hüneburg R; Nattermann J; Strassburg CP; Spengler U
    J Hepatol; 2017 May; 66(5):888-896. PubMed ID: 28040549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sofosbuvir-Daclatasvir-Simeprevir Plus Ribavirin in Direct-Acting Antiviral-Experienced Patients With Hepatitis C.
    Hézode C; Fourati S; Chevaliez S; Scoazec G; Soulier A; Varaut A; François M; Ruiz I; Roudot-Thoraval F; Mallat A; Pawlotsky JM
    Clin Infect Dis; 2017 Jun; 64(11):1615-1618. PubMed ID: 28369411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term effects of the new direct antiviral agents (DAAs) therapy for HCV-related mixed cryoglobulinaemia without renal involvement: a multicentre open-label study.
    Mazzaro C; Dal Maso L; Quartuccio L; Ghersetti M; Lenzi M; Mauro E; Bond M; Casarin P; Gattei V; Crosato IM; De Vita S; Pozzato G
    Clin Exp Rheumatol; 2018; 36 Suppl 111(2):107-114. PubMed ID: 29465371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PegIFNα/ribavirin/protease inhibitor combination in severe hepatitis C virus-associated mixed cryoglobulinemia vasculitis.
    Saadoun D; Resche Rigon M; Pol S; Thibault V; Blanc F; Pialoux G; Karras A; Bazin-Kara D; Cazorla C; Vittecoq D; Musset L; Peltier J; Decaux O; Ziza JM; Lambotte O; Cacoub P
    J Hepatol; 2015 Jan; 62(1):24-30. PubMed ID: 25135864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sofosbuvir and Simeprevir for Treatment of Recurrent Hepatitis C Infection After Liver Transplant.
    Nair S; Satapathy SK; Gonzalez HC
    Exp Clin Transplant; 2017 Jun; 15(3):314-319. PubMed ID: 26926117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.